Oxford BioMedica ( (GB:OXB) ) has shared an update.
Oxford Biomedica announced that Pippa Radcliffe, closely associated with the company’s Chief Innovation Officer, Dr. Kyriacos Mitrophanous, exercised 1,209 options and sold 1,209 shares at £2.9785 per share. This transaction, compliant with EU Market Abuse Regulation, reflects internal financial activities and may impact stakeholders’ perceptions of the company’s governance and financial health.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, the company is a pioneer in viral vector development, collaborating with leading pharmaceutical and biotechnology firms. OXB offers expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vectors, with capabilities ranging from early-stage development to commercialization. Headquartered in Oxford, UK, it operates facilities in the UK, France, and the US.
YTD Price Performance: -21.40%
Average Trading Volume: 19,149
Technical Sentiment Signal: Buy
Current Market Cap: $432.5M
Find detailed analytics on OXB stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “Be the Leader You’ve Been Complaining For!” Paramount Stock (NASDAQ:PARA) Dips as Paramount Pulls Out of Politics
- Don’t “Get Rid of All Your Engine Designers”: Ford Stock (NYSE:F) Dips as it Brings Back a Big Name in Internal Combustion
- “Advanced Silicon Wafer Tests” Start; Intel Stock (NASDAQ:INTC) Slips